| Full text | |
| Author(s): |
Zanetti, Marcus V.
[1, 2, 3]
;
Otaduy, Maria C.
[4]
;
de Sousa, Rafael T.
[3]
;
Gattaz, Wagner F.
[1, 3]
;
Busatto, Geraldo F.
[1, 2]
;
Leite, Claudia C.
[4]
;
Machado-Vieira, Rodrigo
[1, 5, 3]
Total Authors: 7
|
| Affiliation: | [1] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, BR-05508 Sao Paulo - Brazil
[2] Univ Sao Paulo, Dept & Inst Psychiat, Lab Psychiat Neuroimaging, LIM 21, BR-05508 Sao Paulo - Brazil
[3] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci LIM 27, Mood Disorders Program, BR-05508 Sao Paulo - Brazil
[4] Univ Sao Paulo, Dept Radiol, BR-05508 Sao Paulo - Brazil
[5] NIMH, ETPB, NIH, Bethesda, MD 20892 - USA
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; v. 18, n. 6 APR 2015. |
| Web of Science Citations: | 12 |
| Abstract | |
Background: The hippocampus has been highly implicated in the pathophysiology of bipolar disorder (BD). Nevertheless, no study has longitudinally evaluated hippocampal metabolite levels in bipolar depression under treatment with lithium. Methods: Nineteen medication-free BD patients (78.9% treatment-naive and 73.7% with BD type II) presenting an acute depressive episode and 17 healthy controls were studied. Patients were treated for 6 weeks with lithium in an open-label trial. N-acetyl aspartate (NAA), creatine, choline, myo-Inositol, and glutamate levels were assessed in the left hippocampus before (week 0) and after (week 6) lithium treatment using 3T proton magnetic resonance spectroscopy (1H-MRS). The metabolite concentrations were estimated using internal water as reference and voxel segmentation for partial volume correction. Results: At baseline, acutely depressed BD patients and healthy controls exhibited similar hippocampal metabolites concentrations, with no changes after 6 weeks of lithium monotherapy. A significant correlation between antidepressant efficacy and increases in NAA concentration over time was observed. Also, there was a significant positive correlation between the changes in glutamate concentrations over follow-up and plasma lithium levels at endpoint. Mixed effects model analysis revealed a bimodal effect of lithium plasma levels in hippocampal glutamate concentrations: levels of 0.2 to 0.49 mmol/L (n=9) were associated with a decrease in glutamate concentrations, whereas the subgroup of BD subjects with ``standard{''} lithium levels (>= 0.50 mmol/L; n = 10) showed an overall increase in glutamate concentrations over time. Conclusions: These preliminary results suggest that lithium has a bimodal action in hippocampal glutamate concentration depending on the plasma levels. (AU) | |
| FAPESP's process: | 13/03905-4 - NEUROBIOLOGICAL DIFFERENCES BETWEEN TREATMENT-NAIVE PATIENTS WITH BIPOLAR DISORDER SUBTYPES I AND II |
| Grantee: | Marcus Vinicius Zanetti |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 09/14891-9 - Longitudinal study on the neuroprotective and neurotrophic effects of lithium in bipolar disorder: identification of cellular and molecular targets clinically relevant |
| Grantee: | Rodrigo Machado-Vieira |
| Support Opportunities: | Research Grants - Young Investigators Grants |